Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DiaMedica Therapeutics Inc DMAC

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.


NDAQ:DMAC - Post by User

Bullboard Posts
Comment by StockscoutXon Oct 14, 2018 2:00pm
94 Views
Post# 28797592

RE:RE:RE:RE:RE:US LISTING

RE:RE:RE:RE:RE:US LISTINGThe problem for now is that the market has been spooked with the manipulation of the SP to trigger the march 20, 2018 private placement.

This was one of the conditions to trigger the selling of those :
The volume-weighted average closing trading price of the Common Shares on any recognized Canadian stock exchange equals or exceeds USD$0.60 for a period of 21 consecutive trading days,  The link to this info : Private Placement

Therefore, the SP run up to nearly 90 cents cdn which triggered the selling condition in hind sight seems orchestrated because after the selloff it also seems very odd that the SP has such a hard time going back up. Futhermore, DiaMedica Therapeutics and Ahon Pharma, signing of license agreement for DM199 in China for Acute ischemic stroke has had virtually no impact to restart an upward trend. Licensing agreement

So far what I have observed since the end of the selloff, every time the SP is about to move upwards it has been knocked down or a wall was put up but I have not seen none of that when the SP did a run up to nearly 90 centrs to trigger a sell condition from the PP.

Whatever it all means makes it uneasy to deal with this stock. It could explain very much the SP movement or manipulation.

All in my opinion.
Bullboard Posts